The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Stephen P. Carey net worth and biography

Stephen Carey Biography and Net Worth

CFO of ANI Pharmaceuticals

Mr. Carey has been the Company’s Vice President, Finance and Chief Financial Officer since May 2016, and a Sr. Vice President since December 2020. From June 2007 to October 2015, Mr. Carey held various executive financial positions at Par Pharmaceutical Companies, Inc., including Senior Vice President, Controller and Principal Accounting Officer. Prior to that, Mr. Carey held various financial and accounting positions at Schering-Plough Corporation. Mr. Carey has over 25 years of experience as a financial executive, 20 of which are in the pharmaceutical industry. Mr. Carey began his career at PricewaterhouseCoopers. Mr. Carey graduated from Montclair State University with a B.S. degree in Accounting.

How old is Stephen P. Carey?: Mr. Carey is currently 53 years old. There are 8 older executives and no younger executives at ANI Pharmaceuticals. The oldest executive at ANI Pharmaceuticals is Mr. James G. Marken, Senior Vice President of Operations, who is 61 years old. Learn More on Stephen P. Carey's age.
How do I contact Stephen P. Carey?: The corporate mailing address for Mr. Carey and other ANI Pharmaceuticals executives is 210 Main Street West, Baudette MN, 56623. ANI Pharmaceuticals can also be reached via phone at (218) 634-3500 and via email at [email protected]. Learn More on Stephen P. Carey's contact information.
Has Stephen P. Carey been buying or selling shares of ANI Pharmaceuticals?: Stephen P. Carey has not been actively trading shares of ANI Pharmaceuticals during the past quarter. Learn More on Stephen P. Carey's trading history.
Who are ANI Pharmaceuticals' active insiders?: ANI Pharmaceuticals' insider roster includes Stephen Carey (CFO), Thomas Haughey (Director), Nikhil Lalwani (Pres), Muthusamy Shanmugam (Head of R&D and COO), Jeanne Thoma (Director), and Patrick Walsh (Director). Learn More on ANI Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ANI Pharmaceuticals?: During the last year, insiders at the specialty pharmaceutical company sold shares 39 times. They sold a total of 371,731 shares worth more than $23,601,729.53. The most recent insider tranaction occured on October, 14th when VP Meredith Cook sold 250 shares worth more than $14,297.50. Insiders at ANI Pharmaceuticals own 12.7% of the company. Learn More about insider trades at ANI Pharmaceuticals.
Information on this page was last updated on 10/14/2024.

Stephen P. Carey Insider Trading History at ANI Pharmaceuticals

Stephen P. Carey Buying and Selling Activity at ANI Pharmaceuticals

ANI Pharmaceuticals Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Today's Range

Now: $55.63

$54.75

$56.38

50 Day Range

MA: $58.35

$55.10

$61.74

2 Week Range

Now: $55.63

$48.20

$70.81

Volume

74,099 shs

Average Volume

218,154 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Financial Prophecy

From Porter & Company | Ad